Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2021-01-20 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Trading Halt 3 pages 214.3KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Cyclopharm Limited regarding a trading halt requested pending the release of an announcement related to a capital raising involving a placement of new shares. It is a short notice informing the market about the trading halt and the reason for it, without containing any financial statements or detailed financial data. The document length is 3730 characters, which is relatively short and fits the profile of an announcement rather than a full report. The content clearly indicates it is about a trading halt and capital raising announcement, not the actual capital raising details or financial report. Therefore, it fits best under Capital/Financing Update (CAP).
2021-01-20 English
USFDA Approval Progress for Technegas and Business Update 4 pages 125.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Cyclopharm Limited providing an update on the progress towards USFDA approval for their product Technegas, preliminary unaudited revenue performance for FY20, and other operational matters. It includes forward-looking statements about expected USFDA approval timing, sales model, litigation updates, and corporate governance considerations such as potential board appointments. The document is addressed to the Australian Securities Exchange and is styled as a business update rather than a formal financial report. It contains no detailed financial statements or comprehensive financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not contain earnings highlights typical of an Earnings Release (ER), nor is it a transcript, audit report, or legal proceeding report. The document is a corporate announcement providing operational and regulatory progress updates, revenue guidance, and governance intentions. This fits best with the category Capital/Financing Update (CAP), as it discusses progress on regulatory approval (which impacts capital markets), revenue performance, and potential board changes in anticipation of market entry. The document length and content exclude it from being a mere report publication announcement (RPA) or regulatory filing (RNS). Therefore, the most appropriate classification is CAP with high confidence.
2021-01-13 English
Bell Potter Healthcare Conference 25 pages 6.9MB
Investor Presentation Classification · 95% confidence The document is titled 'Cyclopharm Bell Potter Healthcare Conference' and dated 26 November 2020. It is an investor update presentation by the CEO & Managing Director. The content includes company overview, product details, market opportunities, clinical guidelines, reimbursement information, and competitive advantages of the company's nuclear medicine product Technegas®. The document is structured as a presentation with slides, images, and bullet points, focusing on financial and strategic information for investors. There are no financial statements, audit opinions, or regulatory filings included. It is not a transcript of a call, nor an announcement of voting results or legal proceedings. The document is a detailed presentation aimed at investors, covering financials, strategy, and market position. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2020-11-25 English
Change of Director's Interest Notice TM 2 pages 162.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific notification of director share transactions.
2020-10-21 English
Change of Director's Interest Notice 2 pages 215.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific regulatory filing about director share transactions.
2020-09-30 English
Change of Director's Interest Notice 2 pages 215.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including the number of shares acquired and disposed, nature of interest, and dates. This matches the description of a Director's Dealing report, which involves personal share transactions by company directors and executives. The document is concise and focused solely on director share transactions, with no financial statements or broader company information. Therefore, it fits the 'Director's Dealing' category (DIRS).
2020-09-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.